In vitro and in silico methods are foreseen in the EU regulation REACH, to prioritize more dangerous compounds, to focus expensive experiments, by reducing animal tests and to fill the data gaps. A brief historical introduction of QSAR modelling and the importance of model validation according to the OECD principles for reliable predictions is presented
